2023
Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study
Clark E, Perin J, Herrmann N, Brawman‐Mintzer O, Lanctôt K, Lerner A, Mintzer J, Padala P, Rosenberg P, Sami S, Shade D, van Dyck C, Porsteinsson A, Group F. Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2023, 9: e12403. PMID: 37538343, PMCID: PMC10394740, DOI: 10.1002/trc2.12403.Peer-Reviewed Original ResearchNeuropsychiatric symptomsEffects of methylphenidateAlzheimer's diseaseSecondary analysisNeuropsychiatric Inventory scoresElation/euphoriaSymptoms of apathyIndividual neuropsychiatric symptomsPresentation of symptomsImpact of methylphenidateIndividual domain scoresAppetite/Catecholaminergic dysfunctionMonth 6Neuropsychiatric InventoryCaregiver scoresNPI domainsNew symptomsTreatment periodDomain scoresMeaningful improvementsMethylphenidateSymptomsPlaceboDisease
2022
Examining the effects of age and sex on tau PET binding in the absence of beta‐amyloid pathology
Gordon B, Flores S, Dincer A, Keefe S, McKay N, Hobbs D, Wisch J, Hornbeck R, Franklin E, Jack C, Koeppe R, Xiong C, McDade E, van Dyck C, Klein G, Pariente J, Bateman R, Morris J, Perrin R, Benzinger T. Examining the effects of age and sex on tau PET binding in the absence of beta‐amyloid pathology. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.063285.Peer-Reviewed Original ResearchPrimary age-related tauopathyTau-PET bindingTau-PETTemporal gyrusPET bindingBeta-amyloid pathologyAge-related tauopathyRostral middle frontal gyrusSubthreshold levelsElevated tracer uptakeTau PET imagingTau bindingInferior temporal gyrusInferior temporal cortexMiddle frontal gyrusSuperior temporal gyrusEffect of ageAlzheimer pathologyAmyloid pathologySignificant positive associationLateral parietalTemporal cortexTracer uptakeAlzheimer's diseaseSecondary analysis